Advanced Nuclear Medicine Ingredients
Radiometals labeled radiopharmaceuticals and a global service provider in the radiopharmaceutical field.
Employees
Enterprise value
$6m
| Date | Investors | Amount | Round |
|---|---|---|---|
€5.2m Valuation: €5.2m | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 25 % | 200 % | - | 133 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (63 %) | (40 %) | (3 %) | (33 %) | 14 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (25 %) | (20 %) | 17 % | (10 %) | 43 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
More about Advanced Nuclear Medicine Ingredients
EditANMI SA is a pharmaceutical company developing innovative radiopharmaceutical solutions and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the scalable synthesis of “theranostic” radiopharmaceuticals and to ease their daily production in hospitals and radiopharmacies. ANMI's vision is focused on increasing patient access to new highly specific theranostic radiopharmaceuticals through streamlined and cost-effective production processes.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads